FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic mutation
The U.S. Food and Drug Administration on Friday approved a drug to treat lung and thyroid cancers driven by a specific genetic mutation that Eli Lilly and Co acquired with its 2019 purchase of Loxo Oncology.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Genetics | Health | Thyroid | Thyroid Cancer